OABI
OmniAb, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.74
P/S
9.39
EV/EBITDA
-3.59
DCF Value
$-0.38
FCF Yield
-21.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
73.5%
Operating Margin
-383.1%
Net Margin
-347.0%
ROE
-24.0%
ROA
-70.6%
ROIC
-24.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $8.4M | $-14.2M | $-0.11 |
| FY 2025 | $18.7M | $-64.8M | $-0.57 |
| Q3 2025 | $2.2M | $-16.5M | $-0.14 |
| Q2 2025 | $3.9M | $-15.9M | $-0.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.87
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.